Lake Street assumed coverage of InfuSystem (INFU) with a Buy rating and a price target of $15, up from $12.50. The “leading provider” of infusion pumps and related services, operating under two complementary platforms of Patient Services and Device Solutions, is “laying the groundwork for durable and profitable growth that investors may not fully appreciate today,” the analyst argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INFU: